This final conversation touches on prescribing models and the increasing challenge keeping patients in long-term clinical trials, after which Roger Green asks a final question.
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
